Two Core Mechanisms, One Fundamental Tension
MicroRNA therapeutics work through two primary modalities, and understanding the distinction is essential to reading the patent landscape accurately. The first is miRNA inhibition — the antimiR or antagomir strategy — which deploys chemically modified antisense oligonucleotides to silence overexpressed, disease-driving miRNAs known as oncomiRs. The second is miRNA replacement or mimicry, which introduces synthetic double-stranded RNA mimics to restore tumor-suppressive miRNAs that are epigenetically silenced or deleted in disease tissue.
The landmark antimiR example in this dataset is miravirsen, an LNA-modified antisense oligonucleotide targeting miR-122 for hepatitis C infection, developed by Santaris Pharma (Denmark) and described entering Phase 2 clinical trials in 2012. On the mimic side, the most cited example is the combinatorial delivery of miR-34 and let-7 mimics for non-small cell lung cancer, developed at Yale University (2014), which demonstrated tumor suppression and survival advantage in Kras;p53 mouse models.
MicroRNAs are endogenous, approximately 20–23 nucleotide non-coding RNAs that post-transcriptionally suppress gene expression. A single miRNA may regulate hundreds of downstream genes — making miRNAs fundamentally distinct from siRNA. Their pleiotropic nature is simultaneously their greatest therapeutic asset (simultaneous suppression of entire oncogenic networks) and their most significant liability (off-target effects in non-disease tissues).
Chemical modification strategies explored across retrieved records include locked nucleic acid (LNA), 2′-O-methyl, phosphorothioate backbone, and peptide nucleic acid (PNA) chemistries — each designed to improve binding affinity, nuclease resistance, and pharmacokinetics. The Medical Research Council (UK, 2010) demonstrated PNA-mediated miR-155 inhibition in primary B cells and in vivo mouse models without requiring transfection agents, a meaningful step toward systemic deployability. Sub-domains identified in this dataset also include nanoparticle-based delivery, computational miRNA target identification, miRNA sponge/decoy constructs, TALEN-based gene editing of miRNA loci, and small molecule-mediated miRNA modulation.
Miravirsen, an LNA-modified antisense oligonucleotide targeting miR-122 developed by Santaris Pharma, entered Phase 2 clinical trials for hepatitis C infection and represents the field’s first clinical-stage miRNA therapeutic compound.
Three Phases of Innovation: From Concept to Clinical Reassessment
The publication record in this dataset spans 2007 to 2023 and reveals a clear three-phase trajectory that any R&D or IP team should use to calibrate their positioning relative to the field’s maturity curve.
The Early Foundational Phase (2007–2012) was characterised by conceptual framing of miRNA as therapeutic targets and the development of antisense oligonucleotide inhibition chemistries. The University of British Columbia (2008) and East Carolina University (2007) established the conceptual foundation; Santaris Pharma’s 2012 miravirsen paper marked the field’s first genuine clinical-stage milestone.
The Development and Delivery Phase (2013–2019) represents the largest cluster of retrieved records. This phase is defined by intensive work on delivery vehicles, combinatorial approaches, and the articulation of key barriers. Notable contributions include combinatorial miRNA nanodelivery from Yale University (2014), antimiR chemistry refinement from Santaris Pharma (2012), and the development of the miRNA Polysome Shift Assay pharmacodynamic tool by Regulus Therapeutics (2015) — a direct measurement tool for miRNA inhibition by anti-miRNA drugs in vivo.
The Maturation and Critical Reassessment Phase (2020–2023) reflects honest appraisal of clinical translation failures. Records from Jiangxi Institute (2021) and Mylan Laboratories (2021) document the gap between miRNA and siRNA clinical progress explicitly. Simultaneously, novel nanoformulation strategies and carrier-free supramolecular miRNA designs represent genuine recent innovation signals. According to WHO frameworks for assessing emerging therapeutic classes, this reassessment phase is a normal precursor to more focused, mechanism-validated clinical development.
“As of late 2021, fewer than 20 miRNA-targeting molecules had entered clinical trials, with none reaching Phase III — compared to over 60 siRNA clinical candidates and two approvals.”
Explore the full miRNA therapeutics patent and literature dataset in PatSnap Eureka — search, filter, and analyse in real time.
Explore Patent Data in PatSnap Eureka →The Delivery Bottleneck: Where the Real IP Race Is Being Run
Across the entire dataset spanning 2007–2023, in vivo delivery is consistently identified as the rate-limiting barrier to clinical translation of miRNA therapeutics — and therefore the single highest-leverage R&D investment area in this landscape. Multiple delivery architectures are represented across retrieved records, including nanostructured lipid carriers (NLCs), viral vectors, polymeric nanoparticles, exosome-based vehicles, and novel carrier-free supramolecular designs.
The most clinically proximate delivery insight from this dataset comes from the strategic implications section: lessons from Patisiran (2018) and givosiran (2019) — including LNP formulation parameters, safety profiling frameworks, and regulatory strategy — are described as directly applicable to miRNA mimic development. First movers who port validated siRNA delivery technologies to miRNA payloads may compress development timelines significantly, according to multiple retrieved records from Mylan Laboratories and the National University of Singapore (2021).
The most novel delivery signal in the dataset is the IacsRNA approach from Xi’an Jiaotong University (2022), which engineers miRNA into auric-sulfhydryl coordination supramolecular nanostructures without traditional carrier vehicles. This carrier-free design directly addresses the two leading liabilities of miRNA therapeutics — systemic instability and immunogenicity of lipid-based carriers — through structural self-sufficiency. Guidance from FDA on oligonucleotide drug product development, and relevant EMA reflection papers on RNA-based therapeutics, provide the regulatory scaffolding against which these delivery innovations will ultimately be assessed.
Nanostructured lipid carriers (NLCs) for miRNA delivery are described in the literature as having low toxicity, low immunogenicity, and being amenable to surface modification for tumor targeting, based on research from Guizhou Province Key Laboratory (2018).
Retrieved records articulate a fundamental mechanistic liability: the broad multi-gene targeting of miRNAs creates both therapeutic opportunity and off-target toxicity risk. IP strategies and clinical programs should be designed around tissue-specific delivery as the primary specificity mechanism, rather than relying on inherent sequence selectivity alone.
Application Domains: Oncology Dominates, But the Edges Are Expanding
Oncology constitutes the overwhelming majority of retrieved therapeutic records — estimated at more than 70% of literature results in this dataset — spanning solid tumors including lung, breast, ovarian, prostate, and colorectal cancers, as well as hematological malignancies. Two core strategies predominate: oncomiR inhibition and tumor suppressor miRNA replacement.
Oncology: Multi-Target Suppression and Drug Resistance
The Yale University (2014) combinatorial miR-34/let-7 nanodelivery work demonstrated tumor suppression and survival advantage in Kras;p53 mouse models. Massachusetts General Hospital and Harvard (2020) described screening of miRNAs targeting MGMT and ABCB1 efflux proteins to resensitise glioblastoma cells — a direct application to multi-drug resistance, one of oncology’s most persistent clinical problems. MD Anderson Cancer Center (2021) documented the intersection of miR-21 targeting and oncomiR networks with PD-1 checkpoint blockade outcomes in melanoma, signalling an emerging combinatorial immuno-oncology strategy.
Infectious Disease: The Most Clinically Validated Domain
Infectious disease represents the most clinically validated miRNA therapeutic application in this dataset. Beyond miravirsen for HCV, Dartmouth College (2023) demonstrated that human miRNA let-7b-5p can impair Pseudomonas aeruginosa biofilm formation and antibiotic resistance — a finding with significant implications for the antimicrobial resistance (AMR) crisis tracked by WHO. The same paper introduced the Rocket-miR software tool for cross-species miRNA-mRNA interaction prediction. For SARS-CoV-2, Mashhad University (2021) described SARS-CoV-2-encoded miRs and host miRNA exploitation strategies, though the druggability of miRNAs in antiviral contexts remains actively debated.
Cardiovascular Disease and Emerging Niches
Cardiovascular disease is positioned alongside cancer and HCV as one of the three lead application areas for miRNA therapeutics, according to the Hubrecht Institute (2014). The University of Colorado (2020) identified miR-21 as a shared therapeutic target across ischemia/reperfusion injury, coronary artery disease, stroke, and obesity — an example of the pleiotropic targeting advantage. An emerging niche documented in this dataset is pediatric cancer: Case Western Reserve University (2019) applied network science to identify safe miRNA cocktails for Ewing sarcoma, explicitly accounting for toxicity to housekeeping gene networks.
Oncology constitutes more than 70% of retrieved miRNA therapeutic literature records, spanning solid tumors including lung, breast, ovarian, prostate, and colorectal cancers, as well as hematological malignancies, based on a dataset of over 80 patent and literature records spanning 2007–2023.
Map miRNA therapeutic applications across disease areas using PatSnap Eureka’s AI-powered landscape analysis.
Analyse Applications in PatSnap Eureka →Geographic and Assignee Landscape: Distributed, Academic, and Still Early
The United States dominates miRNA therapeutics innovation by volume, accounting for approximately 40% of retrieved records. Key US institutional contributors include Yale University, Ohio State University, MD Anderson Cancer Center, Massachusetts General Hospital/Harvard, Case Western Reserve University, Regulus Therapeutics (San Diego), and Dana-Farber/Harvard. This concentration of academic medical centre involvement reflects both the basic science intensity of the field and the relative absence of large pharma commitment at this stage.
China is the second-largest contributor, with institutions including Harbin Medical University, Nanjing University, Xi’an Jiaotong University, Peking University, and the Chinese Academy of Sciences. The sole patent record in this dataset — filed by Shanghai MicroMedMark Biotech Co., Ltd. in an IL jurisdiction in 2012 — indicates early Chinese company internationalisation of miRNA biomarker intellectual property. Europe shows meaningful concentration, particularly in Denmark (Santaris Pharma, now part of Roche — the field’s most commercially prominent early-stage entity), Italy (IRCCS SDN Naples), the Netherlands (Hubrecht Institute), Poland (Nicolaus Copernicus University), and the UK (University of Manchester, Medical Research Council, Cambridge University).
Asia-Pacific beyond China includes South Korea (National Cancer Center Korea, Generoath), Taiwan (National Yang-Ming University, National Chiao Tung University), Japan (Kyoto University), Singapore (National University of Singapore), Malaysia (Sunway University, University Kebangsaan Malaysia), and Vietnam (Ho Chi Minh City Open University). The most identifiable commercial entities across the full dataset are Santaris Pharma (Denmark, now Roche), Regulus Therapeutics (US), Asuragen (US), and Shanghai MicroMedMark Biotech (China). This distributed academic landscape reflects the pre-commercial maturity of the field — and signals that IP positioning remains genuinely open for well-capitalised entrants.
The United States accounts for approximately 40% of retrieved miRNA therapeutics records, with key contributors including Yale University, MD Anderson Cancer Center, and Regulus Therapeutics. China is the second-largest contributor, with institutions including Harbin Medical University and Xi’an Jiaotong University. The most identifiable commercial entities are Santaris Pharma (now part of Roche), Regulus Therapeutics, Asuragen, and Shanghai MicroMedMark Biotech.
Emerging Directions and Strategic Whitespace for IP Teams
Records from 2020–2023 in this dataset signal five distinct emerging innovation vectors, each with implications for R&D prioritisation and IP filing strategy. The convergence of deep learning drug discovery tools, novel delivery chemistries, and previously underexplored application domains creates a landscape where strategic positioning — not just scientific capability — will determine who captures value.
1. Carrier-Free Supramolecular miRNA Nanodrugs
Xi’an Jiaotong University’s 2022 IacsRNA approach — engineering miRNA into auric-sulfhydryl coordination nanostructures without traditional carrier vehicles — directly addresses the two leading liabilities of miRNA therapeutics: systemic instability and immunogenicity of lipid-based carriers. This structural self-sufficiency approach represents a meaningful departure from the LNP-centric delivery paradigm that has dominated the field since 2015.
2. Deep Learning for Small Molecule–miRNA Modulation
The DeepsmirUD framework (2022) deploys competing deep learning architectures to predict whether small molecule compounds will up- or down-regulate specific miRNAs — providing a computational drug discovery pathway that completely circumvents oligonucleotide delivery challenges. The Psmir database from Harbin Medical University (2016) had already identified 6,501 candidate associations between 1,295 small molecules — including 624 FDA-approved drugs — and 25 miRNAs, creating a drug repurposing foundation that AI tools can now systematically exploit. The NIH National Center for Advancing Translational Sciences has separately documented computational approaches to RNA target identification as a priority area for accelerating clinical translation.
3. miRNA-Based Antimicrobials Against Drug-Resistant Bacteria
The Rocket-miR paper from Dartmouth College (2023) represents the newest application frontier in this dataset: deploying human miRNAs as novel antimicrobials against antibiotic-resistant pathogens — specifically demonstrating that let-7b-5p impairs Pseudomonas aeruginosa biofilm formation and antibiotic resistance. With a bioinformatics platform designed for rapid cross-species target identification, this approach positions miRNA therapeutics as a potential tool in the AMR arsenal at a moment when the global pipeline of conventional antibiotics is critically thin.
4. Checkpoint Immunotherapy Integration
The intersection of miRNA biology with PD-1/CTLA-4 checkpoint blockade — documented by MD Anderson Cancer Center (2021) in the context of melanoma outcomes — signals an emerging combinatorial strategy: using miRNA modulation to either prime immunotherapy response or overcome checkpoint resistance. This combinatorial approach, if validated, would represent a meaningful IP whitespace given that oncology and HCV have monopolised miRNA therapeutic attention to date.
5. Combinatorial miRNA Strategies as Differentiated IP Space
Both the Yale University (2014) combinatorial miR-34/let-7 work and the Case Western Reserve University (2019) Ewing sarcoma cocktail paper demonstrate that multi-miRNA combination approaches may overcome the single-agent efficacy limitations that have halted Phase II programs. Filing composition-of-matter IP around validated miRNA combinations with defined delivery formats is described in retrieved records as a meaningful whitespace for strategically oriented IP teams.
“Antimicrobial and immunotherapy-adjacent applications represent underexplored IP territory — oncology and HCV have monopolised miRNA therapeutic attention, potentially leaving antimicrobial and immuno-oncology combination applications as relatively uncrowded filing spaces.”